Table 3. Univariate and multivariate analyses of association between clinicopathological variables and organ sites of metastasis in patients of resected lung adenocarcinoma.

Variables	Univariate			Multivariate
	HR	95% CI	P value	HR	95% CI	P value
Contralateral lung metastasis
Age*	1.012	0.993 to 1.032	0.223	1.007	0.984 to 1.031	0.557
Female	0.740	0.478 to 1.145	0.176	0.836	0.502 to 1.393	0.493
Tumor size†	1.681	1.446 to 1.953	< 0.001	1.306	1.081 to 1.579	0.006
N2 (vs. N0 or N1)	5.661	3.423 to 9.363	< 0.001	2.000	1.013 to 3.948	0.046
Stage II or III (vs. stage I)	6.811	4.287 to 10.821	< 0.001	3.034	1.519 to 6.059	0.002
Visceral pleural invasion	2.693	1.601 to 4.527	< 0.001	1.704	0.951 to 3.053	0.073
Angiolymphatic invasion	3.449	2.188 to 5.437	< 0.001	1.411	0.819 to 2.433	0.215
Acinar predominant	0.502	0.309 to 0.814	0.005	0.468	0.250 to 0.877	0.018
Papillary predominant	1.378	0.854 to 2.223	0.189
Micropapillary predominant	2.296	1.358 to 3.881	0.002	0.868	0.425 to 1.775	0.699
Solid predominant	1.996	1.113 to 3.580	0.020	0.633	0.281 to 1.429	0.271
Brain metastasis
Age*	0.987	0.967 to 1.007	0.211	0.985	0.961 to 1.010	0.230
Female	1.005	0.634 to 1.595	0.983	0.917	0.537 to 1.566	0.751
Tumor size†	1.593	1.367 to 1.856	< 0.001	1.276	1.045 to 1.559	0.017
N2 (vs. N0 or N1)	5.065	2.992 to 8.573	< 0.001	1.657	0.821 to 3.347	0.159
Stage II or III (vs. stage I)	7.190	4.385 to 11.790	< 0.001	2.469	1.201 to 5.076	0.014
Visceral pleural invasion	2.131	1.253 to 3.621	0.005	1.179	0.650 to 2.136	0.588
Angiolymphatic invasion	4.195	2.586 to 6.805	< 0.001	1.818	1.037 to 3.189	0.037
Acinar predominant	0.551	0.332 to 0.916	0.021	1.009	0.497 to 2.046	0.980
Papillary predominant	0.731	0.412 to 1.298	0.285
Micropapillary predominant	3.776	2.247 to 6.343	< 0.001	2.686	1.270 to 5.683	0.010
Solid predominant	2.002	1.083 to 3.700	0.027	1.284	0.530 to 3.112	0.579
Bone metastasis
Age*	1.004	0.982 to 1.026	0.715	0.995	0.969 to 1.022	0.726
Female	0.656	0.400 to 1.075	0.095	0.667	0.374 to 1.188	0.169
Tumor size†	1.762	1.496 to 2.075	< 0.001	1.388	1.127 to 1.710	0.002
N2 (vs. N0 or N1)	6.849	3.989 to 11.759	< 0.001	2.727	1.259 to 5.910	0.011
Stage II or III (vs. stage I)	6.240	3.724 to 10.457	< 0.001	1.481	0.653 to 3.356	0.347
Visceral pleural invasion	2.389	1.338 to 4.268	0.003	1.305	0.685 to 2.487	0.418
Angiolymphatic invasion	5.253	3.117 to 8.853	< 0.001	2.447	1.347 to 4.446	0.003
Acinar predominant	0.637	0.376 to 1.077	0.092	0.995	0.472 to 2.097	0.990
Papillary predominant	0.733	0.398 to 1.348	0.317
Micropapillary predominant	2.107	1.169 to 3.799	0.013	1.459	0.627 to 3.391	0.380
Solid predominant	3.198	1.768 to 5.784	< 0.001	1.588	0.664 to 3.800	0.299
Liver metastasis
Age*	0.991	0.951 to 1.034	0.682	0.985	0.939 to 1.033	0.527
Female	0.458	0.170 to 1.233	0.122	0.550	0.187 to 1.617	0.277
Tumor size†	1.586	1.234 to 2.038	< 0.001	1.255	0.879 to 1.791	0.212
N2 (vs. N0 or N1)	6.236	2.394 to 16.244	< 0.001	2.538	0.645 to 9.996	0.183
Stage II or III (vs. stage I)	6.111	2.261 to 16.518	< 0.001	1.163	0.235 to 5.757	0.853
Visceral pleural invasion	2.215	0.715 to 6.862	0.168
Angiolymphatic invasion	6.789	2.359 to 19.536	< 0.001	3.599	1.126 to 11.507	0.031
Acinar predominant	0.561	0.198 to 1.589	0.276
Papillary predominant	0.376	0.086 to 1.653	0.195
Micropapillary predominant	1.231	0.350 to 4.329	0.746
Solid predominant	6.987	2.675 to 18.245	< 0.001	2.929	0.958 to 8.954	0.059

HR, Hazard ratio; CI, confidence interval.

^*The HR associated with age is that the increase in hazard is associated with a 1-year increase in age.

^†The HR associated with tumor size is associated with a 1-cm increase in size.